CBAF — CITBA Financial Corporation — heads into the end of April as one of the more thinly positioned names on the OTC market, with short sellers having steadily unwound their bets over the past three months.
The most telling story here is the collapse in short positioning. Short interest has fallen more than 77% since late January, dropping from roughly 1,509 shares to just 337 as of mid-February. That is a near-total retreat. Official FINRA data as of mid-April puts reported short interest at just 2 shares — effectively zero by any practical measure. At 0.02% of the free float, there is no meaningful short thesis in this stock right now.
The lending market reflects that same indifference. Availability is entirely unused — utilization has been flat at 0% every session for the past six weeks, having never exceeded 50% even at the highest point of the past year. Cost to borrow last printed around 2.8%, a modest level consistent with a stock that nobody is urgently seeking to borrow. Both the short interest and cost-to-borrow readings are now stale by more than 70 days, which means these figures describe conditions from February rather than today — the absence of any new activity is itself informative.
Price action adds limited colour. The stock closed at $39.61 on April 27, down fractionally on both the day and the week. The one-month decline is just over 1%, well within normal noise for an illiquid OTC name. There are only two institutional holders on record — Siena Capital Partners with a 4% stake and PL Capital Advisors with just under 2%, both last reported at year-end 2025. Neither has made a material change recently.
What to watch here is straightforward: with utilization at zero, borrow activity non-existent, and institutional ownership concentrated in two small holders, any meaningful shift in volume or a fresh short-interest reading would stand out sharply against the current flatline.
See the live data behind this article on ORTEX.
Open CBAF on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
